Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Werewolf Therapeutics Inc (HOWL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.09+1.87%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for HOWL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash runway into late 2026 | It plans to keep cash until late 2026. | Intact | cash runway guidance falls short of late 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, high-risk biotechnology business, not a proven durable compounder. The thesis is currently intact, supported by strong recent financial performance, but confidence is low and earnings quality remains loss-making.
The evidence snapshot gives no valuation measure or clear account of market expectations, so whether HOWL looks cheap or expensive versus peers is unclear. The market may be weighing recent results and sector momentum against losses, high risk, and uncertainty around the merger and cash runway.
Near term, reported results may remain uneven: 2026-Q2 included collaboration revenue from the JZP898 asset sale and net income, unlike the prior-year quarter, but the evidence does not establish that this revenue will recur. Cash fell from March to June, while management projected funding into 2027-Q2 under its current plan; merger completion and execution remain unproven.
The multi-year thesis hinges on completing the Ambros merger and extending the cash runway as planned. Near term, a guidance cut or continued weakening in job growth could weigh on the business backdrop, while continued strength from healthcare bellwethers could support sector momentum.
Over the next one to three years, HOWL combines a strong recent result and a healthcare-sector tailwind with losses, high risk, and important execution questions. The long-term thesis remains intact, but confidence is low and depends on merger completion and cash discipline. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company focuses on its INDUCER T-cell platform. |
| Under Pressure |
| company abandons INDUCER T-cell platform in 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce losses and improve EPS estimates | A primary condition in Werewolf Therapeutics Inc's published investment case. The stated target is EPS loss narrows to better than -$1.27 in FY26. | Intact | EPS loss worsens beyond -$1.27 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating expenses via workforce reduction | A primary condition in Werewolf Therapeutics Inc's published investment case. The stated target is Reduce workforce by at least 60% by mid-2026. | Recovered | workforce reduction falls below 60% by mid-2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “• Research and development expenses: Research and development expenses were $6.2 million for the second quarter of 2026, compared to $13.1 million for the same period in 2025.” “• Research and development expenses: Research and development expenses were $8.2 million for the first quarter of 2026, compared to $13.1 million for the same period in 2025.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.59 → $-0.59 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-07-25 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-07-26 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-07-27 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-07-28 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-07-29 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-07-30 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-07-31 | $-1.59 | $0 | 2 / 2 |
| 2026-08-01 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-02 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-03 | $-1.59 | $0 | 2 / 2 |
| 2026-08-04 | $-1.59 | $0 | 2 / 2 |
| 2026-08-05 | $-1.59 | $0 | 2 / 2 |
| 2026-08-06 | $-1.59 | $0 | 2 / 2 |
| 2026-08-07 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-08 | $-1.59 | $0 | 2 / 2 |
| 2026-08-09 | $-1.59 | $0 | 2 / 2 |
| 2026-08-10 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-12 | $-1.59 | $0 | 2 / 2 |
| 2026-08-13 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-14 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-15 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-16 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-17 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-18 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-19 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-20 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-21 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-22 | $-1.59 | $3,100,000 | 1 / 1 |
| 2026-08-23 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-08-24 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-08-25 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-08-26 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-08-27 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-08-28 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-08-29 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-08-30 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-08-31 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-01 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-02 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-03 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-04 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-05 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-06 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-07 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-08 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-09 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-10 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-11 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-12 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-13 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-14 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-15 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-16 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-17 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-18 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-19 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-20 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-21 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-22 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-23 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-24 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-25 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-26 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-27 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-28 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-29 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-09-30 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-01 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-02 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-03 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-04 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-05 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-06 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-07 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-08 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-09 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-10 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-11 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-12 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-13 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-14 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-15 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-16 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-17 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-18 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-19 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-20 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-21 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-22 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-23 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-24 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-25 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-26 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-27 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-28 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-29 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-30 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-10-31 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-11-01 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-11-02 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-11-03 | $-0.59 | $3,100,000 | 1 / 1 |
| 2026-11-04 | $-0.59 | $3,100,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.